California's Stem Cell Agency Receives a $1 Billion Validation
Roche's purchase pushes Poseida stock 215 percent higher
The $1 billion sale of Poseida Therapeutics last week is good news for California’s stem cell and gene therapy agency, which is looking for stories to demonstrate its impact on the search for revolutionary therapies.
The state agency, officially called the California Institute for Regenerative Medicine (CIRM), has invested $24 million in Pos…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.